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osting by EAbstract Duchenne and Becker muscular dystrophy (DMD and BMD) are caused, in the majority
of cases, by deletions in the dystrophin gene (DMD). The disease is an X-linked neuromuscular dis-
eases typically caused by disrupting (DMD) or non-disrupting (BMD) the reading frame in the dys-
trophin (DMD) gene. In the present study, ampliﬁcations of the genomic DNAs of unrelated 15
Saudi DMD males were carried out using multiplex polymerase chain reaction (PCR) for nine-hot-
spot regions of exons 4, 8, 12, 17, 19, 44, 45, 48 and 51. We detected six Saudi patients having dele-
tions in a frequency of 40%. The frequency of deletions in exon 51 (20%) was the most common
deletion frequently associated with our Saudi sample males. Exons 19, 45, and 48 were present in
a frequency of 6.7% each. All deletions were recognized as an individual exonic deletions, while
no gross deletion where detected. Finally, the molecular deletions in the Saudi males was expected
to be characterized by a moderate frequency among different populations due to the geographical
KSA region, which it is in the crossroad of intense migrations and admixture of people coming from
continental Asia, Africa, and even Europe. In conclusion, attempts to include an extra DNA sam-
ples might reﬂect a valid vision of the deletions within the high frequency deletion regions
(HFDR’s) in the DMD gene mutations in KSA.
ª 2010 King Saud University. All rights reserved.1. Introduction
Duchenne muscular dystrophy (DMD, MIM #310200) and its
milder allelic variant, Becker muscular dystrophy (BMD), areail.com
ity. All rights reserved. Peer-
d University.
lsevierboth caused by mutations in the dystrophin gene (DMD, MIM
#300377) located on Xp21. DMD represents the most common
genetic neuromuscular disease of childhood. It is relatively fre-
quent, with an incidence of 1 in 3500 male livebirth (Worton
and Thompson, 1988).
Symptoms in DMD patients start to appear at the age of
3 years with progressive muscle weakness. The patient is non
ambulatory by the age of 9 or 10 years and usually by 20 years
old; death will occur after cardiac or respiratory complications
(Sbiti et al., 2002). DMD is the more severe phenotype of mus-
cular dystrophies (Lo et al., 2006). BMD is the allelic and the
milder form of DMD, but it is less frequent in which the birth
prevalence is 1 in 18,500 live born male (Zhou et al., 2006;
Figure 1 Multiplex PCR of the human DMD gene electrophore-
sed on a 3% NuSieve gel-ethidium dye. ‘C’ represented ‘normal
control male’ with no deletions, MW is size marker (100 bp
ladder). Lanes 1, 2, 3, and 4 showed missing of exon 19, 51, 45 and
48, respectively.
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gression in which the mean age of the onset of symptoms such
as muscle weakness and poor walking, arise around 12 years of
age. Loss of ambulation varies from adolescence to adulthood
(Ramellia et al., 2006), while death generally occurs in the third
or fourth decade (Sbiti et al., 2002).
The DMD gene consists of 79 exons and encodes a 14-kb
mRNA (Koenig et al., 1988; Ahn and Kunkel, 1993; Freund
et al., 2007). The protein product of the gene, with a molecular
weight of 427 kDa, is a sarcolemma-associated protein, which
binds cytoskeletal actin through its N-terminal domain, and a
complex of dystrophin associated proteins (DAP) through its
C-terminal domain (Ahn and Kunkel, 1993). Intragenic dele-
tions and duplications together account for over two thirds
of the mutations leading to DMD and BMD (Koenig et al.,
1989; den Dunnen et al., 1989).
Intragenic deletions and duplications together account for
over two thirds of mutations leading to DMD and BMD (den
Dunnen et al., 1989; Koenig et al., 1989). Most can be detected
bymultiplex PCR (Beggs andKunkel, 1990; Chamberlain et al.,
1988) and are clustered in two high frequency deletion regions
(HFDRs), one in the 50 (centromeric) portion of the gene, the
other in the 30 half of the gene (Baumbach et al., 1989; Kim
et al., 2002; Koenig et al., 1989). A small proportion ranging
from 0% to 6% of the mutations within the dystrophin gene
involves duplications (Hu et al., 1990; Mendell et al., 2001).
More than 200 dystrophin point mutations are known (http://
www.dmd.nl/). Previous study of dystrophin deletionmutations
in Saudi males (Al-Jumah et al., 2002) has not dealt with the
frameshifting hypothesis.
In the present paper, we presented an analysis of exceptions
to the frameshift rule and their implications for dystrophin in
males.Table 1 Exon deletion frequencies in 15 unrelated DMD
Saudi patients.
Exon(s) deleted No. of
deletions
Deletion
frequency (%)
Exon 19 1 6.7
Exon 45 1 6.7
Exon 48 1 6.7
Exon 51 3 20.0
Total deletions 6 402. Subjects and methods
Dystrophin patients were selected from Saudi dystrophin fam-
ilies registered in the database records in neurologic out-patient
clinics of governmental and military hospitals, and Handi-
capped Children Societies in Western Saudi regions. Informed
consents were obtained from all patients’ family. Clinical data
sheet of a patient was registered on the database records of
Molecular Genetics laboratory in the Department of Medical
Genetics, Faculty ofMedicine, UmmAl-Qura University. Clin-
ical information was independent of any molecular data of
DMD gene or its protein. For the sake of accuracy, we excluded
the patients who lacked clinical evidence of the disease.
We categorized patients according to the severity of the
phenotype of the disease, as ‘DMD’ if they were conﬁned to
a wheelchair at or before the age of 12 years and as ‘BMD’
if they were still ambulant at age 16 years. Patients were clas-
siﬁed as intermediate (B/DMD) if they became wheelchair
bound (WCB) between the ages of 12 and 16 years (Hodgson
et al., 1989). They deﬁned as ‘ND – not determined’ phenotype
if the patient was not wheelchair bound or too young to be
diagnosed as BMD. Our sample contained 15 unrelated pro-
band males. The age of the DMD patients ranged from 5.0
to 19.0 years of a mean age ± standard deviation (SD) was
11.8 ± 3.4 years. Diagnosis of DMD/BMD probands included
elevated serum creatine phosphokinase (CPK), age of onset,
calf pseudohypertrophy, age of wheelchair conﬁnement, pres-ence of cardiomyopathy, and myopathic changes to EMG pat-
tern (http://www.dmd.nl/).
2.1. DNA analysis
Genomic DNA was isolated from EDTA-peripheral leuko-
cytes using Mini Spin-Column protocol (QIAGEN, USA).
Multiplex PCR of the high frequency deletion regions in the
DMD gene was performed (Fig. 1). The ampliﬁcation was car-
ried out using multiple 18 primers ﬂanking exons 4, 8, 12, 17,
19, 44, 45, 48, and 51 (Chamberlain et al., 1988). PCR cycling
was programmed as: initial denaturing at 95 C for 6 min (1
round), then 95 C for 30 s; 53 C for 30 s, 65 C for 4 min (re-
peated for 23 rounds), and an initially extension 65 C for
7 min. PCR products were separated on 3% NuSieve agarose.
The gel was photographed using Gel Documentation and
Analysis System (UVitec, Cambridge, UK).
Table 2 Clinical data and molecular ﬁnding of dystrophin Saudi patients within the high frequency deletion regions (HFDR’s).
Fam. no.a Ageb (y) Sex Diagnosisc WCBd (y) F.H.e Exon deletedf Frame-shiftg
1 15 M DMD 4 + 19 +
5 7 M ND   51 +
8 14 M DMD/BMD 12  45 +
9 11 M DMD 8 + 51 +
12 15 M DMD 9  51 +
20 9 M ND  + 48 
a These numbers only refer to one affected proband.
b The age of initial examination.
c Patients were classiﬁed as intermediate (B/DMD) if they became wheelchair bound (WCB) between the ages of 12 and 16 y (Dubowitz,
1990). Patients labeled as ‘not determined’ ‘‘ND’’ were too young to permit a deﬁnitive diagnosis, and are grouped separately (Table 1).
d Wheelchair bound.
e Family history (F.H.) considered (+) if there are more than one affected individuals in the family and () if the affected male was a sporadic
case.
f Deletion detection were focused to the high frequency deletion regions including exons 4, 8, 12, 17, 19, 44, 45, 48, and 51.
g In-frame () and outframeshift (+) were assigned according to Monaco et al. (1988).
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3.1. Deletion analysis
To detect DMD gene deletions in Chamberlain’s set, genomic
DNA was successfully ampliﬁed. The DMD deletion frequency
was 40% (6 of 15 patients). The missing exons in the central
region represented the majority of deletions (83%) conﬁned
to exons 51, 48 and 45, while the remaining deletions (27%)
were represented only in exon 19 in the proximal region. These
results might be in agreement with the Egyptian studies
(Elhawary et al., 2004) and other comparative studies in Asian
populations (Lu et al., 2006; Hwa et al., 2007; Hallwirth-Pillay
et al., 2007; Hassan et al., 2008; Marini et al., 2008). In the
present study, the deletion frequency of exon 51 was the most
common deletion (20%), while exons 19, 45 and 48 showed a
frequency of 6.7% each (Table 1). All deletions recognized in
this study were detected as an individual exonic deletions,
while no gross deletion where detected.
Again, the deletion frequency in the Saudi DMD patients
(40%) is relatively lower than other Arabs or neighboring pop-
ulations, but comparable with most of the Asian data (Hassan
et al., 2008; Marini et al., 2008; Hwa et al., 2007). In the North
countries of Africa, Egypt, for example, represented a rela-
tively high frequency of DMD gene deletion frequency (51%;
78/152) (Elhawary et al., 2004), which is the case in Moroccan
population (51%; 37/72) (Sbiti et al., 2002).
Our data results might lie between that of the highest fre-
quency in Turk (60%) (Onengut et al., 2000) and the lowest dele-
tion frequency in Philippines (33%) (Cutiongeo et al., 1995).
Some Asian populations, for example, Pakistani (40.75%)
(Hassan et al., 2008), Malaysian (42%) (Marini et al., 2008),
Chinese (49%) (Lu et al., 2006) and Taiwanese (35.3%) (Hwa
et al., 2007) have nearly the same magnitudes and patterns of
deletion frequencies to this Saudi study. This might be rational-
ized as strong genetic linkage or genetic drifts.
3.1.1. In-frame and out-frameshifting and DMD phenotypes
A hypothesis known as the reading-frame hypothesis proposes
that deletions that alter the reading frame of dystrophin
mRNA produce no functional dystrophin and cause severeDMD, while in-frame deletions may produce partly-functional
internally deleted dystrophin leading to the milder Becker dis-
ease (Monaco et al., 1988).
Deletion of exon 19 resulted in a disruption of the reading
frame, resulting in the severe DMD phenotypes. Deletion of
exon 45 resulted in the intermediate D/BMD phenotype
(Table 2). On the other hand, deletion of exon 51 gave rise
to severe DMD phenotypes as shown in two cases (#11 and
#15) and in ‘not determined phenotypes’ phenotype in (#7)
that might be suspected to have DMD phenotype. Deletions
due to exons (4, 8, 12, 17 and 44) have never been shown dele-
tions. Our results agreed the frameshift rule in a frequency of
(66.7%) of patients. This result showed a high concordance
with Monaco et al. (1988) besides other relevant studies
(Elhawary et al., 2004; Lu et al., 2006; Hassan et al., 2008;
Marini et al., 2008; Hwa et al., 2007). The deviation from
the frameshift hypothesis was not clearly shown because of
the presence of ND phenotypic cases.
In conclusion, the molecular deletions in the Saudi males
should be expected to characterize a moderate frequency. This
might be due to the geographical KSA region, where it is in the
crossroad of intense migrations and admixture of people
coming from continental Asia, Africa, and even Europe.
Attempts to involve an extra DNA samples might reﬂect the
real map of the deletions within the high frequency deletion
regions (HFDR’s) in the DMD gene mutations in KSA.
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